# OnCo record idea-tr2-biomarker-cwe (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-tr2-biomarker-cwe/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-tr2-biomarker-cwe" ;
  schema:name "Pay for new biomarker tests only while evidence of clinical utility is being collected"@en ;
  schema:description "Most genomic and liquid biopsy tests are reimbursed on analytical validity and association with outcome, not on proof that they improve care. Paying for new oncology biomarker tests only inside registries or randomised studies, as Medicare did for PET, would sort the useful from the useless."@en ;
  schema:url <https://onco.cc/ideas/idea-tr2-biomarker-cwe/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamaoncol.2021.7239> ;
  onco:related <https://onco.cc/ideas/idea-tr2-payer-combo-cwe/> ;
  onco:terms <https://onco.cc/terms/real-world-evidence/>, <https://onco.cc/terms/companion-diagnostic-term/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-biomarker-validation/>, <https://onco.cc/bottlenecks/b-drug-pricing/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-fernandez-jama-oncol/> .